Expression of Interferon Lambda 4 Is Associated with Reduced Proliferation and Increased Cell Death in Human Hepatic Cells

Journal of Interferon and Cytokine Research

Volumn 35, Issue 11, 2015, Pages 888-900

  Onabajo, Olusegun O ^a   Porter Gill, Patricia ^a   Paquin, Ashley ^a   Rao, Nina ^a   Liu, Luyang ^a   Tang, Wei ^a   Brand, Nathan ^a   Prokunina Olsson, Ludmila ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOCKING ANTIBODY; CXCL11 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERFERON; INTERFERON LAMBDA 4; MESSENGER RNA; RETINOIC ACID INDUCIBLE PROTEIN I; STAT1 PROTEIN; UNCLASSIFIED DRUG; CXCL10 PROTEIN, HUMAN; CYTOKINE RECEPTOR; IFNL4 PROTEIN, HUMAN; IFNLR1 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; IP10-MIG RECEPTOR; MONOCLONAL ANTIBODY; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE RELEASE; GENE EXPRESSION PROFILING; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; UNFOLDED PROTEIN RESPONSE; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; GENETICS; HEP-G2 CELL LINE; HEPACIVIRUS; HEPATITIS C; IMMUNOLOGY; LIVER CELL CARCINOMA; LIVER TUMOR; PATHOLOGY; PHYSIOLOGY; RNA INTERFERENCE; TUMOR CELL LINE; VIROLOGY;

ANTIBODIES, MONOCLONAL; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOKINE CXCL10; HEP G2 CELLS; HEPACIVIRUS; HEPATITIS C; HEPATOCYTES; HUMANS; INTERLEUKINS; LIVER NEOPLASMS; RECEPTORS, CYTOKINE; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84943613789     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2014.0161     Document Type: Article

References (42)

1. Aka PV, Kuniholm MH, Pfeiffer RM, Wang AS, Tang W, Chen S, Astemborski J, Plankey M, Villacres MC, Peters MG, Desai S, Seaberg EC, Edlin BR, Strickler HD, Thomas DL, Prokunina-Olsson L, Sharp GB, O'Brien TR. 2014. Association of the IFNL4-DeltaG allele with impaired spontaneous clearance of hepatitis C virus. J Infect Dis 209(3): 350-354
2. Aksoy MO, Yang Y, Ji R, Reddy PJ, Shahabuddin S, Litvin J, Rogers TJ, Kelsen SG. 2006. CXCR3 surface expression in human airway epithelial cells: cell cycle dependence and effect on cell proliferation. Am J Physiol Lung Cell Mol Physiol 290(5):L909-L918
3. Amanzada A, Kopp W, Spengler U, Ramadori G, Mihm S. 2013. Interferon-lambda4 (IFNL4) transcript expression in human liver tissue samples. PLoS One 8(12):e84026
4. Bantel H, Schulze-Osthoff K. 2003. Apoptosis in hepatitis C virus infection. Cell Death Differ 10 (Suppl 1):S48-S58
5. Dill MT, Duong FH, Vogt JE, Bibert S, Bochud PY, Terracciano L, Papassotiropoulos A, Roth V, Heim MH. 2011. Interferon- induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 140(3):1021-1031
6. Eslam M, Hashem AM, Leung R, Romero-Gomez M, Berg T, Dore GJ, Chan HL, Irving WL, Sheridan D, Abate ML, Adams LA, Mangia A, Weltman M, Bugianesi E, Spengler U, Shaker O, Fischer J, Mollison L, Cheng W, Powell E, Nattermann J, Riordan S, McLeod D, Armstrong NJ, Douglas MW, Liddle C, Booth DR, George J, Ahlenstiel G; International Hepatitis CGC. 2015. Interferon-lambda rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. Nat Commun 6:6422
7. Festjens N, Vanden Berghe T, Vandenabeele P. 2006. Necrosis, a well-orchestrated form of cell demise: signalling cascades, important mediators and concomitant immune response. Biochim Biophys Acta 1757(9-10):1371-1387
8. Fiers W, Beyaert R, Declercq W, Vandenabeele P. 1999. More than one way to die: apoptosis, necrosis and reactive oxygen damage. Oncogene 18(54):7719-7730
9. Fujino H, Imamura M, Nagaoki Y, Kawakami Y, Abe H, Hayes CN, Kan H, Fukuhara T, Kobayashi T, Masaki K, Ono A, Nakahara T, Honda Y, Naeshiro N, Urabe A, Yokoyama S, Miyaki D, Murakami E, Kawaoka T, Hiraga N, Tsuge M, Hiramatsu A, Hyogo H, Aikata H, Takahashi S, Miki D, Ochi H, Ohishi W, Chayama K; Hiroshima Liver Study Group. 2013. Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C. J Gastroenterol 49(12):1548-1556
10. Galluzzi L, Vitale I, Abrams JM, Alnemri ES, Baehrecke EH, Blagosklonny MV, Dawson TM, Dawson VL, El-Deiry WS, Fulda S, Gottlieb E, Green DR, Hengartner MO, Kepp O, Knight RA, Kumar S, Lipton SA, Lu X, Madeo F, Malorni W, Mehlen P, Nunez G, Peter ME, Piacentini M, Rubinsztein DC, Shi Y, Simon HU, Vandenabeele P, White E, Yuan J, Zhivotovsky B, Melino G, Kroemer G. 2012. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ 19(1):107-120
11. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. 2009. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461(7262):399-401
12. Hamming OJ, Terczynska-Dyla E, Vieyres G, Dijkman R, Jorgensen SE, Akhtar H, Siupka P, Pietschmann T, Thiel V, Hartmann R. 2013. Interferon lambda 4 signals via the IFNlambda receptor to regulate antiviral activity against HCV and coronaviruses. EMBO J 32(23):3055-3065
13. Harvey CE, Post JJ, Palladinetti P, Freeman AJ, Ffrench RA, Kumar RK, Marinos G, Lloyd AR. 2003. Expression of the chemokine IP-10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation. J Leukoc Biol 74(3):360-369
14. Hassel BA, Zhou A, Sotomayor C, Maran A, Silverman RH. 1993. A dominant negative mutant of 2-5A-dependent RNase suppresses antiproliferative and antiviral effects of interferon. EMBO J 12(8):3297-3304
15. Huybrechts SJ, Van Veldhoven PP, Brees C, Mannaerts GP, Los GV, Fransen M. 2009. Peroxisome dynamics in cultured mammalian cells. Traffic 10(11):1722-1733
16. Key FM, Peter B, Dennis MY, Huerta-Sanchez E, Tang W, Prokunina-Olsson L, Nielsen R, Andres AM. 2014. Selection on a variant associated with improved viral clearance drives local, adaptive pseudogenization of interferon lambda 4 (IFNL4). PLoS Genet 10(10):e1004681
17. Konishi H, Motomura T, Matsumoto Y, Harimoto N, Ikegami T, Yoshizumi T, Soejima Y, Shirabe K, Fukuhara T, Maehara Y. 2013. Interferon-lambda4 genetic polymorphism is associated with the therapy response for hepatitis C virus recurrence after a living donor liver transplant. J Viral Hepat 21(6):397-404
18. Lagging M, Romero AI, Westin J, Norkrans G, Dhillon AP, Pawlotsky JM, Zeuzem S, von Wagner M, Negro F, Schalm SW, Haagmans BL, Ferrari C, Missale G, Neumann AU, Verheij-Hart E, Hellstrand K; DITTO-HCV Study Group. 2006. IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. Hepatology 44(6):1617-1625
19. Liang TJ, Ghany MG. 2013. Current and future therapies for hepatitis C virus infection. N Engl J Med 368(20):1907-1917
20. Lim R, Knight B, Patel K, McHutchison JG, Yeoh GC, Olynyk JK. 2006. Antiproliferative effects of interferon alpha on hepatic progenitor cells in vitro and in vivo. Hepatology 43(5):1074-1083
21. Lippincott-Schwartz J, Snapp E, Kenworthy A. 2001. Studying protein dynamics in living cells. Nat Rev Mol Cell Biol 2(6):444-456
22. Liu M, Guo S, Stiles JK. 2011. The emerging role of CXCL10 in cancer (Review). Oncol Lett 2(4):583-589
23. Lu YF, Goldstein DB, Urban TJ, Bradrick SS. 2015. Interferonlambda4 is a cell-autonomous type III interferon associated with pre-treatment hepatitis C virus burden. Virology 476:334-340
24. Meissner EG, Bon D, Prokunina-Olsson L, Tang W, Masur H, O'Brien TR, Herrmann E, Kottilil S, Osinusi A. 2014a. IFNL4-DeltaG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin. J Infect Dis 209(11):1700-1704
25. Meissner EG, Wu D, Osinusi A, Bon D, Virtaneva K, Sturdevant D, Porcella S, Wang H, Herrmann E, McHutchison J, Suffredini AF, Polis M, Hewitt S, Prokunina-Olsson L, Masur H, Fauci AS, Kottilil S. 2014b. Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. J Clin Invest 124(8):3352-3363
26. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. 2013. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 57(4):1333-1342
27. Murakawa M, Asahina Y, Nakagawa M, Sakamoto N, Nitta S, Kusano-Kitazume A, Watanabe T, Kawai-Kitahata F, Otani S, Taniguchi M, Goto F, Nishimura-Sakurai Y, Itsui Y, Azuma S, Kakinuma S, Watanabe M. 2015. Impaired induction of interleukin 28B and expression of interferon lambda 4 associated with nonresponse to interferon-based therapy in chronic hepatitis C. J Gastroenterol Hepatol 30(6):1075-1084
28. Murata M, Nabeshima S, Kikuchi K, Yamaji K, Furusyo N, Hayashi J. 2006. A comparison of the antitumor effects of interferon-alpha and beta on human hepatocellular carcinoma cell lines. Cytokine 33(3):121-128
29. O'Brien TR, Pfeiffer RM. 2015. Reply: subgroup differences in response to 8 weeks of ledipasvir/sofosbuvir for chronic hepatitis C. Open Forum Infect Dis 1(3):ofu110; DOI: 10.1093/ofid/ofu110
30. O'Brien TR, Prokunina-Olsson L, Donnelly RP. 2014. IFNlambda4: the paradoxical new member of the interferon lambda family. J Interferon Cytokine Res 34(11):829-838
31. Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H, Hergott D, Porter-Gill P, Mumy A, Kohaar I, Chen S, Brand N, Tarway M, Liu L, Sheikh F, Astemborski J, Bonkovsky HL, Edlin BR, Howell CD, Morgan TR, Thomas DL, Rehermann B, Donnelly RP, O'Brien TR. 2013. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 45(2):164-171
32. Rysiecki G, Gewert DR, Williams BR. 1989. Constitutive expression of a 2¢,5¢-oligoadenylate synthetase cDNA results in increased antiviral activity and growth suppression. J Interferon Res 9(6):649-657
33. Sheahan T, Imanaka N, Marukian S, Dorner M, Liu P, Ploss A, Rice CM. 2014. Interferon lambda alleles predict innate antiviral immune responses and hepatitis C virus permissiveness. Cell Host Microbe 15(2):190-202
34. Snapp EL, Altan N, Lippincott-Schwartz J. 2003. Measuring protein mobility by photobleaching GFP chimeras in living cells. Curr Protoc Cell Biol Chapter 21:Unit 21.1
35. Takaoka A, Hayakawa S, Yanai H, Stoiber D, Negishi H, Kikuchi H, Sasaki S, Imai K, Shibue T, Honda K, Taniguchi T. 2003. Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature 424(6948):516-523
36. Takaoka A, Taniguchi T. 2003. New aspects of IFN-alpha/beta signalling in immunity, oncogenesis and bone metabolism. Cancer Sci 94(5):405-411
37. Terczynska-Dyla E, Bibert S, Duong FH, Krol I, Jorgensen S, Collinet E, Kutalik Z, Aubert V, Cerny A, Kaiser L, Malinverni R, Mangia A, Moradpour D, Mullhaupt B, Negro F, Santoro R, Semela D, Semmo N; Swiss Hepatitis C Cohort Study Group, Heim MH, Bochud PY, Hartmann R. 2014. Reduced IFNlambda4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes. Nat Commun 5:5699
38. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, Goedert JJ, Kirk GD, Donfield SM, Rosen HR, Tobler LH, Busch MP, McHutchison JG, Goldstein DB, Carrington M. 2009. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461(7265):798-801
39. Uccellini L, Tseng FC, Monaco A, Shebl FM, Pfeiffer R, Dotrang M, Buckett D, Busch MP, Wang E, Edlin BR, Marincola FM, O'Brien TR. 2012. HCV RNA levels in a multiethnic cohort of injection drug users: human genetic, viral and demographic associations. Hepatology 56(1):86-94
40. Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, Cronin KD, Hong L, McKenzie A, Patel K, Shianna KV, McHutchison JG, Goldstein DB, Afdhal N. 2010. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 52(6):1888-1896
41. Vogelstein B, Lane D, Levine AJ. 2000. Surfing the p53 network. Nature 408(6810):307-310
42. Wang BX, Rahbar R, Fish EN. 2011. Interferon: current status and future prospects in cancer therapy. J Interferon Cytokine Res 31(7):545-552